Evidence map›Paper›PMID 42304982›Full record

ArticleAnnals of medicine2026

First-in-human evaluation of [

Jiawei He, Yinzhao Wang, Wei Tang, Xiaomei Gao, Yi Cai, Yongxiang Tang, Shuo Hu

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiawei HeDepartment of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University, Changsha City, Hunan Province, P.R. China.
Yinzhao WangDepartment of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University, Changsha City, Hunan Province, P.R. China.
Wei TangDepartment of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University, Changsha City, Hunan Province, P.R. China.
Xiaomei GaoDepartment of Pathology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University, Changsha City, Hunan Province, P.R. China.
Yi CaiDepartment of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University, Changsha City, Hunan Province, P.R. China.ORCID 0000-0001-7773-2064
Yongxiang TangDepartment of Nuclear Medicine, National Clinical Research Center for Geriatric Disorders, Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital Central South University, Changsha City, Hunan Province, P.R. China.
Shuo HuDepartment of Nuclear Medicine, National Clinical Research Center for Geriatric Disorders, Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital Central South University, Changsha City, Hunan Province, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeurotensin receptor-1 (NTSR1) is a promising target for prostate cancer imaging. This study evaluates the first-in-human NTSR1-directed radiotracer [

methodsIn a single-centre, prospective study, 23 men with biopsy-verified prostate cancer were enrolled at Xiangya Hospital (June 2020-June 2024). Within 7 days before radical prostatectomy, whole-body PET/CT was performed after sequential administration of [

resultsThe median age was 71 years (IQR 66-75); 14 were treatment-naïve and 9 had prior androgen-deprivation therapy (ADT). In untreated patients, [

conclusion[

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingNeurotensinPositron Emission Tomography Computed TomographyProstatic NeoplasmsReceptors, NeurotensinAgedFluorine RadioisotopesGallium RadioisotopesHeterocyclic CompoundsHumansMaleMiddle AgedProspective StudiesProstateProstate-Specific AntigenDipeptidesFluorine RadioisotopesGallium RadioisotopesHeterocyclic CompoundsHeterocyclic Compounds, 1-RingNeurotensinneurotensin type 1 receptorProstate-Specific AntigenPSMA-617RadiopharmaceuticalsReceptors, NeurotensinNTSR1PET/CTProstate cancerPSMA

Identifiers

PMID42304982
PMCPMC13276814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.